54083-22-6

54083-22-6 structure

Name: Zorubicin
Chemical Name: N-[(E)-1-[(2S,4S)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethylideneamino]benzamide
CAS Number: 54083-22-6
Molecular Formula: C₃₄H₃₅N₃O₁₀
Molecular Weight: 645.65600
Catalog: Signaling Pathways Cell Cycle/DNA Damage DNA/RNA Synthesis
Create Date: 2018-08-13 11:29:22
Modify Date: 2024-01-17 18:24:46
Zorubicin (Rubidazon) is a derivative of Daunorubicin (HY-13062A). Zorubicin interacts with topoisomerase II and inhibits DNA polymerases. Zorubicin can be used for the research of acute leukemias and sarcomas[1][2][3][4][5].

Name	N-[(E)-1-[(2S,4S)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethylideneamino]benzamide
Synonyms	Rubidazone ZORUBICIN Zorubicina [INN-Spanish] zorubicine Benzoylhydrazone daunorubicin Zorubicin [INN] daunomycin benzoylhydrazone Zorubicine [INN-French] Rubidazon Zorubicinum [INN-Latin]

Description	Zorubicin (Rubidazon) is a derivative of Daunorubicin (HY-13062A). Zorubicin interacts with topoisomerase II and inhibits DNA polymerases. Zorubicin can be used for the research of acute leukemias and sarcomas[1][2][3][4][5].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase Signaling Pathways >> Cell Cycle/DNA Damage >> DNA/RNA Synthesis
In Vitro	Zorubicin (0.1-1 μg/mL; 0-24 h) affects cell cycle[2]. Zorubicin (0-128 nM/mL; 20 min) dose-dependently inhibits DNA polymerases α and β, and shows preferential inhibition of polymerase α[3]. Cell Cycle Analysis[2]. Cell Line: Human lymphoid cell line Concentration: 0.1-1 μg/mL Incubation Time: 0-24 hours Result: Time-dependently increased G2-accumulations of human lymphoid cells, delayed the traverse through G1 and the G1-S transition. Caused a stepwise accumulation of cells in G2-phase.
In Vivo	Zorubicin (12-18 mg/kg; i.p. 48 h after tumour cells injection) affects leukaemic colony forming units[1]. Zorubicin (0.75-6.0 mg/kg; i.v.) increases plasma histamine concentrations and produces immediate hypotension in anesthetized beagle dogs[3]. Animal Model: Six- to eight-week-old male DBA2 mice with P388 tumour cells[1] Dosage: 12-18 mg/kg Administration: Intraperitoneal injection ; 12-18 mg/kg; 48 h after tumour cells injection Result: Showed a D1/2 value of 1.6 mg/kg for leukaemic colony forming units.

CHEMICAL NAME :: Benzoic acid, (1-(4-((3-amino-2,3,6-trideoxy-alpha,L-lyxo-hexopyran osyl)oxy)-1,2,3,4,6,1 1- hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-na phthacenyl)ethylidene )hydrazide, (2S-cis)-

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: BCPCA6 Biochemical Pharmacology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1958- Volume(issue)/page/year: 38,167,1989 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X2089 No. of Facilities: 8 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 229 (estimated) No. of Female Employees: 82 (estimated)